Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash
This article was originally published in The Pink Sheet Daily
Executive Summary
Formerly legal adversaries, the two companies will co-develop PEG-interferon lambda, currently in Phase Ib for hepatitis C.
You may also be interested in...
ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon
A trial will evaluate PEG-Interferon lambda - a drug Bristol includes among its "string of pearls" - versus Pegasys for the treatment of hepatitis C.
ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon
A trial will evaluate PEG-Interferon lambda - a drug Bristol includes among its "string of pearls" - versus Pegasys for the treatment of hepatitis C.
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.